This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Keith H. Nuechterlein, PhD; Michael J. Gitlin, MD; Kenneth L. Subotnik, PhD
Department of Psychiatry and Biobehavioral Sciences University of California, Los Angeles Room 2240 300 UCLA Medical Plaza Los Angeles, CA 90024-6968

Arch Gen Psychiatry. 1995;52(3):203-205.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THEIR computation of results across studies, Gilbert et al¹ find a mean relapse rate of 53% for patients with schizophrenia participating in neuroleptic withdrawal periods in 29 studies that included matched neuroleptic withdrawal and neuroleptic maintenance groups, with average follow-up of about 10 months. The relapse rate for the matched medication maintenance groups is significantly lower, although 16% of these patients relapsed within the average follow-up period of 10 months despite continuous medication. These studies have in almost all cases involved patients who have been ill for many years, leaving unanswered many critical questions about continuous maintenance medication in the early course of a schizophrenic or schizophreniform illness. Because typical neuroleptic medications have substantial side effects, including the increasing possibility of persistent and potentially irreversible tardive dyskinesia with continued use, clinicians, patients, and their families often face very difficult decisions about long-term continuous maintenance medication in the initial . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?